|
1
|
Galiè N, Humbert M, Vachiery JL, Gibbs S,
Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A,
Beghetti M, et al: 2015 ESC/ERS guidelines for the diagnosis and
treatment of pulmonary hypertension: The joint task force for the
diagnosis and treatment of pulmonary hypertension of the European
society of cardiology (ESC) and the European respiratory society
(ERS): Endorsed by: Association for European paediatric and
congenital cardiology (AEPC), international society for heart and
lung transplantation (ISHLT). Eur Heart J. 37:67–119.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Simonneau G, Montani D, Celermajer DS,
Denton CP, Gatzoulis MA, Krowka M, Williams PG and Souza R:
Haemodynamic definitions and updated clinical classification of
pulmonary hypertension. Eur Respir J. 53(1801913)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Thakkar V and Lau EM: Connective tissue
disease-related pulmonary arterial hypertension. Best Pract Res
Clin Rheumatol. 30:22–38. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shirai Y, Yasuoka H, Okano Y, Takeuchi T,
Satoh T and Kuwana M: Clinical characteristics and survival of
Japanese patients with connective tissue disease and pulmonary
arterial hypertension: A single-centre cohort. Rheumatology
(Oxford). 51:1846–1854. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kang KY, Jeon CH, Choi SJ, Yoon BY, Choi
CB, Lee CH, Suh CH, Lee CW, Cho CS, Nam EJ, et al: Survival and
prognostic factors in patients with connective tissue
disease-associated pulmonary hypertension diagnosed by
echocardiography: Results from a Korean nationwide registry. Int J
Rheum Dis. 20:1227–1236. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hao YJ, Jiang X, Zhou W, Wang Y, Gao L,
Wang Y, Li GT, Hong T, Huo Y, Jing ZC and Zhang ZL: Connective
tissue disease-associated pulmonary arterial hypertension in
Chinese patients. Eur Respir J. 44:963–972. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhao J, Wang Q, Liu Y, Tian Z, Guo X, Wang
H, Lai J, Huang C, Yang X, Li M and Zeng X: Clinical
characteristics and survival of pulmonary arterial hypertension
associated with three major connective tissue diseases: A cohort
study in China. Int J Cardiol. 236:432–437. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fei Y, Shi X, Gan F, Li X, Zhang W, Li M,
Hou Y, Zhang X, Zhao Y, Zeng X and Zhang F: Death causes and
pathogens analysis of systemic lupus erythematosus during the past
26 years. Clin Rheumatol. 33:57–63. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Condliffe R, Kiely DG, Peacock AJ, Corris
PA, Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, et
al: Connective tissue disease-associated pulmonary arterial
hypertension in the modern treatment era. Am J Respir Crit Care
Med. 179:151–157. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fischer A, Denton CP, Matucci-Cerinic M,
Gillies H, Blair C, Tislow J and Nathan SD: Ambrisentan response in
connective tissue disease-associated pulmonary arterial
hypertension (CTD-PAH)-A subgroup analysis of the ARIES-E clinical
trial. Respir Med. 117:254–263. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Coghlan JG, Galiè N, Barberà JA, Frost AE,
Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ,
Simonneau G, et al: Initial combination therapy with ambrisentan
and tadalafil in connective tissue disease-associated pulmonary
arterial hypertension (CTD-PAH): Subgroup analysis from the
AMBITION trial. Ann Rheum Dis. 76:1219–1227. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Weatherald J, Montani D, Jevnikar M, Jaïs
X, Savale L and Humbert M: Screening for pulmonary arterial
hypertension in systemic sclerosis. Eur Respir Rev.
28(190023)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shahane A: Pulmonary hypertension in
rheumatic diseases: Epidemiology and pathogenesis. Rheumatol Int.
33:1655–1667. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Barst RJ, McGoon M, Torbicki A, Sitbon O,
Krowka MJ, Olschewski H and Gaine S: Diagnosis and differential
assessment of pulmonary arterial hypertension. J Am Coll Cardiol.
43 (Suppl 12):40S–47S. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fortuna G and Brennan MT: Systemic lupus
erythematosus: Epidemiology, pathophysiology, manifestations, and
management. Dent Clin North Am. 57:631–655. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
van den Hoogen F, Khanna D, Fransen J,
Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP,
Medsger TA Jr, Carreira PE, et al: 2013 classification criteria for
systemic sclerosis: An American College of rheumatology/European
league against rheumatism collaborative initiative. Arthritis
Rheum. 65:2737–2747. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vitali C, Bombardieri S, Jonsson R,
Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox
RI, Kassan SS, et al: Classification criteria for Sjögren's
syndrome: A revised version of the European criteria proposed by
the American-European consensus group. Ann Rheum Dis. 61:554–558.
2002.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Goldin JG, Lynch DA, Strollo DC, Suh RD,
Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn
S, McNitt-Gray MF, et al: High-resolution CT scan findings in
patients with symptomatic scleroderma-related interstitial lung
disease. Chest. 134:358–367. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tang J, Lei L, Pan J, Zhao C and Wen J:
Higher levels of serum interleukin-35 are associated with the
severity of pulmonary fibrosis and Th2 responses in patients with
systemic sclerosis. Rheumatol Int. 38:1511–1519. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Seror R, Theander E, Brun JG, Ramos-Casals
M, Valim V, Dörner T, Bootsma H, Tzioufas A, Solans-Laqué R, Mandl
T, et al: Validation of EULAR primary Sjögren's syndrome disease
activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis.
74:859–866. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chung L, Liu J, Parsons L, Hassoun PM,
McGoon M, Badesch DB, Miller DP, Nicolls MR and Zamanian RT:
Characterization of connective tissue disease-associated pulmonary
arterial hypertension from REVEAL: Identifying systemic sclerosis
as a unique phenotype. Chest. 138:1383–1394. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zanatta E, Polito P, Famoso G, Larosa M,
De Zorzi E, Scarpieri E, Cozzi F and Doria A: Pulmonary arterial
hypertension in connective tissue disorders: Pathophysiology and
treatment. Exp Biol Med (Maywood). 244:120–131. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Launay D, Sitbon O, Hachulla E, Mouthon L,
Gressin V, Rottat L, Clerson P, Cordier JF, Simonneau G and Humbert
M: Survival in systemic sclerosis-associated pulmonary arterial
hypertension in the modern management era. Ann Rheum Dis.
72:1940–1946. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Callejas-Rubio JL, López-Pérez L,
Moreno-Escobar E and Ortego-Centeno N: Raynaud's phenomenon and
pulmonary arterial hypertension. Lupus. 17(355)2008.PubMed/NCBI View Article : Google Scholar
|
